News

Article

FDA Answers COVID-19 Vaccine Questions

The agency is answering frequently asked questions about the Pfizer–BioNTech COVID-19 vaccine on its website.

On Dec. 17, 2020, FDA posted answers to frequently asked questions about the Pfizer–BioNTech COVID-19 vaccine that the agency granted Emergency Use Authorization (EUA) to on December 11. The FAQ webpage addresses the agency’s reasoning behind the EUA as well as information on the vaccine.

FDA also discusses whether or not the agency believes the Pfizer–BioNTech COVID-19 vaccine will meet the standards for a biologics license application (BLA). “If safety or effectiveness concerns arise with a vaccine under EUA, FDA has the authority to revoke the EUA. However, it is expected that the data supporting the EUA, together with those that will be collected during use of vaccine under EUA and additional data collected from ongoing trials, will be sufficient to support licensure (approval) of a vaccine authorized under EUA,” the agency answered.

The agency also clarified how it plans to gather additional data on the vaccine. “Additional data on vaccine effectiveness will be generated from further follow-up of participants in clinical studies already underway before the EUA was issued, plus studies conducted by the manufacturer or by the US government evaluating effectiveness of the vaccine as used under the EUA,” FDA stated.

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content